Clinical Trial Update: A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4) [Phase 3]

View source ↗

Summary

A Phase 3 study called AZURE-4 is evaluating Brelovitug versus delayed treatment for chronic hepatitis D infection. The trial is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis D

Drugs mentioned

• Brelovitug (BJT-778)

Snippet

Sponsor: Mirum Pharmaceuticals, Inc. | Conditions: Chronic Hepatitis D Infection | Phase 3 | Status: RECRUITING